Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

被引：0
|
作者：
Karima Saboundji
Jean-Bernard Auliac
Maurice Pérol
Géraldine François
Henri Janicot
Marie Marcq
Catherine Dubos-Arvis
Aldo Renault
Florian Guisier
Luc Odier
Radj Gervais
Christos Chouaïd
机构：
[1] CH François-Quesnay,Pneumologie et Oncologie Thoracique
[2] Centre Léon-Bérard,Oncologie
[3] CHU d’Amiens,Pneumologie et Oncologie Thoracique
[4] CHU Clermont-Ferrand,Pneumologie
[5] CHU Vendée,Pneumologie
[6] Centre François-Baclesse,Oncologie
[7] CH François-Mitterrand,Pneumologie
[8] CHU Charles-Nicolle,Pneumologie
[9] Hôpital Nord-Ouest,Pneumologie
[10] CH Intercommunal de Créteil,Pneumologie
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：501 / 507
页数：6
相关论文
共 50 条
  • [31] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
  • [32] Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
    Huan Wang
    Jing Huang
    Xiaojin Yu
    Shuhua Han
    Xing Yan
    Siqing Sun
    Xiaoli Zhu
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1911 - 1911
  • [33] Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
    Liao, Zi-Xian
    Huang, Kuo-Yen
    Kempson, Ivan M.
    Li, Hsin-Jung
    Tseng, S. -Ja
    Yang, Pan-Chyr
    JOURNAL OF CONTROLLED RELEASE, 2020, 324 : 482 - 492
  • [34] Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    EXPERT OPINION ON PHARMACOTHERAPY, 2025,
  • [35] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [36] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [37] Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
    Di Marino, Pietro
    Chiapperino, Cosima
    Primavera, Francesca Chiara
    Martino, Maria Teresa
    Brocco, Davide
    Carella, Consiglia
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    ONCOTARGETS AND THERAPY, 2022, 15 : 407 - 410
  • [38] Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
    Qin, H.
    Wang, S.
    Gao, F.
    Zeng, Z.
    Liu, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S967 - S967
  • [39] Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
    Jia, Caiyan
    Xu, Qian
    Zhao, Lu
    Kong, Fanming
    Jia, Yingjie
    TRANSLATIONAL ONCOLOGY, 2024, 39
  • [40] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
    Bhandari, Shruti
    Dunlap, Neal
    Kloecker, Goetz
    JOURNAL OF THORACIC DISEASE, 2021, 13 (05) : 3230 - 3234
12345